Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Mitoquinone Mesylate

Phase 2Small molecule

AAntipodean Pharmaceuticals, Inc.

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

FrailtyRecruiting

FrailtyPhase 2

Recruiting

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Frailty

NCT06027554

Clinical

Trials by Indication[1]

Non-Alcoholic Fatty Liver Disease1 trial

A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)

Terminated·AAntipodean Pharmaceuticals, Inc.·Phase 2·NCT01167088·110 enrolled

Hepatitis C1 trial

Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C

Completed·AAntipodean Pharmaceuticals, Inc.·Phase 2·NCT00433108·30 enrolled

Frailty1 trial

The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults

Recruiting·UUConn Health·Phase 2·NCT06027554·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Mitoquinone Mesylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mitoquinone Mesylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mitoquinone Mesylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Antipodean Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAntipodean Pharmaceuticals, Inc.

Related News